Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
27 Jul 2022 On business and financial situation The Company releases the press release related to the first half 2022 financial results   Download
27 Jul 2022 On business and financial situation The Company releases the first half 2022 financial results presentation Download
04 Jul 2022 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2022 Download
30 Jun 2022 Other relevant information The Company informs about the dividends payment Download
16 Jun 2022 Other relevant information The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs   Download

Pages

Date Title Description PDF
06 Nov 2018 Información sobre resultados ROVI releases the presentation related to the nine-month period ended 30 September 2018 results. Download
06 Nov 2018 Información sobre resultados ROVI releases the press release related to the nine-month period ended 30 September 2018 results. Download
17 Oct 2018 Buy-back programmes, stabilisation and treasury stock ROVI informs of the resumption of operations with own shares under the liquidity contract Download
17 Oct 2018 Buy-back programmes, stabilisation and treasury stock ROVI informs that Jefferies International Limited has exercised, in full, the greenshoe subscription option Download
08 Oct 2018 Share capital increases and reductions Information on new shares admissions related to the capital increase of ROVI Download

Pages